Allergic diseases are common in pediatrics and can be caused by seasonal pollens, specifically grass, trees, and weeds. In many European countries, sublingual immunotherapy (SLIT) is an accepted form of treatment for allergic rhinitis. However, the Food and Drug Administration (FDA) has not yet approved its use in the United States. This review focuses on the use of SLIT in the form of allergen immunotherapy tablet and liquid droplet to treat allergic rhinitis and allergic conjunctivitis caused by both grass and ragweed pollens in pediatric patients.
Get full access to this article
View all access options for this article.
References
1.
MeltzerEO. Pharmacotherapeutic strategies for allergic rhinitis: matching treatment to symptoms, disease progression, and associated conditions. Allergy Asthma Proc, 2013; 34:301–311.
WallaceDV, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol, 2008; 122:S1–S84.
5.
MeltzerEO, et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin Immunol, 2009; 124:S43–S70.
6.
BartholowAK, et al. A critical review of the effects of inhaled corticosteroids on growth. Allergy Asthma Proc, 2013; 34:391–407.
7.
GentileD, BartholowA, ValovirtaE, ScaddingG, SkonerD. Current and future directions in pediatric allergic rhinitis. J Allergy Clin Immunol Pract, 2013; 1:214–226.
8.
ShamjiMH, DurhamSR. Mechanisms of immunotherapy to aeroallergens. Clin Exp Allergy, 2011; 41:1235–1246.
9.
CalderonMA, et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol, 2011; 127:30–38.
10.
CoxL, et al. New directions in immunotherapy. Curr Allergy Asthma Rep, 2013; 13:178–195.
SikoraJM, TankersleyMS. Perception and practice of sublingual immunotherapy among practicing allergists in the United States: a follow-up survey. Ann Allergy Asthma Immunol, 2013; 110:194–197 e4.
13.
Di BonaD, et al. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol, 2010; 126:558–566.
14.
PajnoGB, et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. Pediatr Allergy Immunol, 2011; 22:803–807.
15.
CoxL, JacobsenL. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol, 2009; 103:451–459; quiz 459–461, 495.
16.
EmmingerW, DurhamSR, RiisB, MaloneyJ, NolteH. The efficacy of single-grass-allergen-immunotherapy-tablet treatment in mono- and multi-sensitized allergic rhinitis patients: findings from a post hoc analysis. J Allergy Clin Immunol, 2009; 123:S75.
17.
MarognaM, et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann Allergy Asthma Immunol, 2007; 98:274–280.
18.
PassalacquaG. The use of single versus multiple antigens in specific allergen immunotherapy for allergic rhinitis: review of the evidence. Curr Opin Allergy Clin Immunol, 2013Dec5 [Epub ahead of print].
19.
Larenas-LinnemannD, et al. Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009–2012. Ann Allergy Asthma Immunol, 2013; 110:402–415 e9.
20.
KimJM, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics, 2013; 131:1155–1167.
21.
SennaG, CaminatiM, CanonicaGW. Safety and tolerability of sublingual immunotherapy in clinical trials and real life. Curr Opin Allergy Clin Immunol, 2013; 13:656–662.
22.
Subcutaneous and sublingual immunotherapy to treat allergic rhinitis/rhinoconjunctivitis and asthma. I:n Comparative Effectiveness Review Summary Guides for Clinicians. Rockville, MD, 2007.
23.
PajnoGB, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol, 2007; 120:164–170.
24.
DahlR, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol, 2008; 121:512–518 e2.
25.
DurhamSR, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol, 2012; 129:717–725 e5.
26.
CaffarelliC, et al. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy, 2000; 55:1142–1147.
27.
WahnU, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol, 2009; 123:160–166 e3.
28.
De CastroG, et al. Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children's real life. Eur Rev Med Pharmacol Sci, 2013; 17:2225–2231.
29.
BufeA, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol, 2009; 123:167–173 e7.
30.
WahnU, et al. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. J Allergy Clin Immunol, 2012; 130:886–893 e5.
31.
BlaissM, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol, 2011; 127:64–71, 71 e1–4.
32.
LinSY, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA, 2013; 309:1278–1288.
33.
StelmachI, et al. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Allergy, 2012; 67:312–320.
34.
CreticosPS, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol, 2013; 131:1342–1349 e6.
35.
NolteH, et al. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Ann Allergy Asthma Immunol, 2013; 110:450–456 e4.
36.
NelsonHS. Sublingual immunotherapy: the U.S. experience. Curr Opin Allergy Clin Immunol, 2013; 13:663–668.
